• Press release
5 min time reading

Strong Q2 performance and solid H1 results, demonstrating the relevance of our health-focused portfolio

  • Corporate news
  • Q2 sales up +4.2% on a like-for-like (LFL) basis, with volume/mix of +1.9%, and price of +2.3%, including:
    • EMEA +3.6%, with solid growth in EDP and SN progressively recovering
    • Americas +4.3%, driven by strong momentum in SN across the region and progressive improvement in EDP in North America
    • APAC +5.2%, with competitive growth in Infant Milk Formula (IMF) China and strong performance of Aqua in Waters
  • H1 2026 sales of €13,936m up +3.5% LFL, with volume/mix up +1.7%, and price up +1.8%
  • H1 2026 recurring operating margin up +12 bps to 13.3%, driven by strong productivity gains amid inflationary pressure
  • Recurring EPS up +0.9% to €1.92, driven by operational performance
  • Free cash flow at €0.9bn
  • 2026 guidance confirmed, in line with mid-term ambition LFL sales growth expected between +3% and +5%, with recurring operating income growing faster than sales

Please find the full Press Release here